Trial reportScientific reports2026
Short term synbiotic supplementation improves hepatic and metabolic outcomes in children with metabolic dysfunction associated steatotic liver disease.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly recognized chronic liver disorder in children and adolescents, particularly among those with obesity and insulin resistance. Given the emerging role of the gut-liver axis in disease pathogenesis, this study aimed to evaluate the effectiveness of synbiotic supplementation in improving biochemical and ultrasonographic outcomes in pediatric MASLD. This double-blind, randomized, placebo-controlled clinical trial was conducted over 8 weeks. A total of 60 participants aged 10-18 years with MASLD were randomly assigned to receive either synbiotics (n = 30) or placebo (n = 30). The synbiotic formulation contained a combination of nine probiotic strains with a prebiotic component, whereas the placebo consisted of prebiotic-only capsules (fructooligosaccharide with sucrose). The primary outcomes were predefined as changes in liver enzyme activities (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and hepatic steatosis grade assessed by ultrasonography, while secondary outcomes included body mass index (BMI) and lipid profile parameters. Between-group differences were analyzed using appropriate statistical models adjusting for baseline values. After 8 weeks, the synbiotics group showed statistically significant reductions in BMI (- 0.70 ± 0.16 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.